{
  "source": "PA-Med-Nec-Viberzi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2081-13\nProgram Prior Authorization/Medical Necessity\nMedication Viberzi® (eluxadoline)\nP&T Approval Date 4/2016, 3/2017, 3/2018, 3/2019, 3/2020, 3/2021, 3/2022, 3/2023, 3/2024,\n4/2025\nEffective Date 7/1/2025\n1. Background:\nViberzi (eluxadoline) is a mu-opioid receptor agonist, indicated for the treatment of irritable\nbowel syndrome with diarrhea (IBS-D) in adults.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Viberzi will be approved based on all of the following criteria:\na. Diagnosis of irritable bowel syndrome with diarrhea (IBS-D)\n-AND-\nb. History of failure, contraindication or intolerance to a tricyclic antidepressant (e.g.,\namitriptyline)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Viberzi will be approved based on the following criterion:\na. Documentation of positive clinical response to Viberzi therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may apply\n© 2025 UnitedHealthcare Services Inc.\n1\n4. References:\n1. Viberzi Prescribing Information. North Chicago, IL: AbbVie, Inc; July 2024.\n2. Lacey, BE, Pimentel, M, Brenner, DM, et. al. ACG Clinical Guideline: Management of Irritable\nBowel Syndrome. Am J Gastroenterol. 2021; 116 (1): 17-44.\n3. Lembo, A., Sultan, S, et. al. AGA Clinical Practice Guideline on the Pharmacological\nManagement of Irritable Bowel Syndrome with Diarrhea. Gastroenterology. 2022;163:137-151\nProgram Prior A",
    " 17-44.\n3. Lembo, A., Sultan, S, et. al. AGA Clinical Practice Guideline on the Pharmacological\nManagement of Irritable Bowel Syndrome with Diarrhea. Gastroenterology. 2022;163:137-151\nProgram Prior Authorization/Medical Necessity – Viberzi\nChange Control\nDate Change\n4/2016 New program.\n7/2016 Added Indiana and West Virginia coverage information.\n11/2016 Administrative change. Added California coverage information.\n3/2017 Annual review. References updated. State mandate reference language\nupdated.\n3/2018 Annual review. References updated.\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n3/2019 Annual review. References updated.\n3/2020 Annual review. References updated.\n3/2021 Annual review. Removed antispasmodic and antidiarrheal agent as a step 1\noption based on updated ACG guidelines.\n3/2022 Annual review. Updated references.\n3/2023 Annual review. Updated references.\n3/2024 Annual review. Increased initial authorization to 12 months.\n4/2024 Annual review. Updated references.\n4/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}